Giuseppe Matteo Reimondo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2149944/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. New England Journal of Medicine, 2007, 356, 2372-2380.	27.0	679
2	Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. Journal of Endocrinological Investigation, 2006, 29, 298-302.	3.3	604
3	AME Position Statement on adrenal incidentaloma. European Journal of Endocrinology, 2011, 164, 851-870.	3.7	435
4	Adrenal Incidentaloma: A New Cause of the Metabolic Syndrome?. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 998-1003.	3.6	300
5	Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1541-1547.	3.6	284
6	Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy. Journal of Urology, 2002, 167, 2361-2367.	0.4	282
7	Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer, 2005, 12, 657-666.	3.1	255
8	Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. European Journal of Endocrinology, 2006, 155, 823-829.	3.7	239
9	Predictors of morbidity and mortality in acromegaly: an Italian survey. European Journal of Endocrinology, 2012, 167, 189-198.	3.7	189
10	Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 827-834.	3.6	180
11	Subclinical Cushing's Syndrome in Adrenal Incidentalomas. Endocrinology and Metabolism Clinics of North America, 2005, 34, 423-439.	3.2	159
12	Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer, 2008, 15, 1043-1053.	3.1	141
13	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	11.4	129
14	The corticotrophinâ€releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome. Clinical Endocrinology, 2003, 58, 718-724.	2.4	109
15	Subclinical Cushing's syndrome: definition and management. Clinical Endocrinology, 2012, 76, 12-18.	2.4	106
16	Colonoscopic Screening and Follow-Up in Patients with Acromegaly: A Multicenter Study in Italy. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 84-90.	3.6	104
17	Management of adrenal incidentaloma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 233-243.	4.7	99
18	Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. Journal of Endocrinological Investigation, 1999, 22, 48-54.	3.3	89

#	Article	IF	CITATIONS
19	Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. European Journal of Endocrinology, 2005, 153, 307-315.	3.7	86
20	Screening of Cushing's syndrome in adult patients with newly diagnosed diabetes mellitus. Clinical Endocrinology, 2007, 67, 225-229.	2.4	81
21	Subclinical Cushing's Syndrome. Pituitary, 2004, 7, 217-223.	2.9	78
22	Hyperhomocysteinemia in Patients with Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3745-3751.	3.6	74
23	Screening of Cushing's Syndrome in Outpatients with Type 2 Diabetes: Results of a Prospective Multicentric Study in Italy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3467-3475.	3.6	70
24	Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e973-e981.	3.6	69
25	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. European Journal of Endocrinology, 2017, 176, 453-461.	3.7	66
26	Acromegaly is associated with increased cancer risk: a survey in Italy. Endocrine-Related Cancer, 2017, 24, 495-504.	3.1	61
27	Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing's syndrome. European Journal of Endocrinology, 2005, 153, 803-809.	3.7	59
28	Secondary hypoadrenalism. Pituitary, 2008, 11, 147-154.	2.9	58
29	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 499-508.	11.4	55
30	Biochemical Markers of Bone and Collagen Turnover in Acromegaly or Cushing's Syndrome. Hormone and Metabolic Research, 1994, 26, 234-237.	1.5	53
31	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. Annals of Internal Medicine, 2022, 175, 325-334.	3.9	53
32	Therapeutic Concentrations of Mitotane (o,p′-DDD) Inhibit Thyrotroph Cell Viability and TSH Expression and Secretion in a Mouse Cell Line Model. Endocrinology, 2010, 151, 2453-2461.	2.8	50
33	New perspectives for mitotane treatment of adrenocortical carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101415.	4.7	49
34	The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome. Clinical Endocrinology, 2001, 54, 609-616.	2.4	48
35	The value of dehydroepiandrosterone sulfate measurement in the differentiation between benign and malignant adrenal masses. European Journal of Endocrinology, 2000, 142, 611-617.	3.7	44
36	Subclinical Cushing's syndrome. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1272-1279.	1.3	41

#	Article	IF	CITATIONS
37	Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer and Prostatic Diseases, 2009, 12, 94-99.	3.9	38
38	Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. European Journal of Endocrinology, 2019, 180, 387-396.	3.7	38
39	GH and IGFâ€I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clinical Endocrinology, 2008, 69, 613-620.	2.4	37
40	Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Frontiers in Endocrinology, 2021, 12, 738848.	3.5	36
41	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	3.6	33
42	Serum levels of bone GLA protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegly: Effects of long-term octreotide treatment. Calcified Tissue International, 1993, 52, 188-191.	3.1	32
43	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. Journal of Clinical Medicine, 2019, 8, 1850.	2.4	31
44	Laboratory differentiation of Cushing's syndrome. Clinica Chimica Acta, 2008, 388, 5-14.	1.1	30
45	Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. European Journal of Endocrinology, 2012, 167, 769-776.	3.7	30
46	Emerging drugs for adrenocortical carcinoma. Expert Opinion on Emerging Drugs, 2008, 13, 497-509.	2.4	29
47	Adrenocortical Carcinoma with Hypercortisolism. Endocrinology and Metabolism Clinics of North America, 2018, 47, 395-407.	3.2	29
48	Growth Hormone (GH) Responses to GH-Releasing Hormone Alone or Combined with Arginine in Patients with Adrenal Incidentaloma: Evidence for Enhanced Somatostatinergic Tone. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1310-1315.	3.6	27
49	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. Hypertension Research, 2020, 43, 500-510.	2.7	26
50	Effects of mitotane on the hypothalamic–pituitary–adrenal axis in patients with adrenocortical carcinoma. European Journal of Endocrinology, 2017, 177, 361-367.	3.7	25
51	Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer. Cancers, 2020, 12, 2615.	3.7	24
52	Thyroid and colorectal cancer screening in acromegaly patients: should it be different from that in the general population?. European Journal of Endocrinology, 2020, 183, D1-D13.	3.7	19
53	Misdiagnosis of Cushing's Syndrome in a Patient Receiving Rifampicin Therapy for Tuberculosis. Hormone and Metabolic Research, 1995, 27, 148-150.	1.5	18
54	The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndrome. European Journal of Endocrinology, 2008, 159, 569-576.	3.7	18

#	Article	IF	CITATIONS
55	Surgical remission of Cushing's syndrome reduces cardiovascular risk. European Journal of Endocrinology, 2014, 171, 127-136.	3.7	17
56	Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas. Journal of Endocrinological Investigation, 2011, 34, e1-e5.	3.3	16
57	Definition of an optimal strategy to evaluate and follow-up adrenal incidentalomas: time for further research. European Journal of Endocrinology, 2009, 161, 529-532.	3.7	14
58	Analysis of BCLI, N363S and ER22/23EK Polymorphisms of the Glucocorticoid Receptor Gene in Adrenal Incidentalomas. PLoS ONE, 2016, 11, e0162437.	2.5	13
59	Preoperative treatment with metyrapone in patients with Cushing's syndrome due to adrenal adenoma: a pilot prospective study. Endocrine Connections, 2018, 7, 1227-1235.	1.9	13
60	Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies. Cancers, 2021, 13, 5255.	3.7	13
61	Circadian profile of serum melatonin in patients with Cushing's syndrome or acromegaly. Journal of Endocrinological Investigation, 1995, 18, 17-24.	3.3	11
62	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. European Journal of Endocrinology, 2021, 184, R51-R59.	3.7	11
63	Doppler echocardiographic patterns in patients with acromegaly. Journal of Endocrinological Investigation, 1995, 18, 613-620.	3.3	10
64	Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. Journal of Endocrinology, 2003, 177, 109-117.	2.6	9
65	Cushing syndrome due to ectopic adrenocorticotropic hormone secretion in a 3-year-old child. Journal of Pediatric Endocrinology and Metabolism, 2011, 24, 219-22.	0.9	9
66	Autonomous hypercortisolism: definition and clinical implications. Minerva Endocrinologica, 2018, 44, 33-42.	1.8	9
67	Management of Adrenal Incidentalomas. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 166-170.	1.2	8
68	Insights on the Natural History of Adrenal Incidentalomas. Annals of Internal Medicine, 2019, 171, 135.	3.9	8
69	Growth Hormone (GH) Responses to GH-Releasing Hormone Alone or Combined with Arginine in Patients with Adrenal Incidentaloma: Evidence for Enhanced Somatostatinergic Tone. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1310-1315.	3.6	8
70	Evaluation of Midnight Salivary Cortisol as a Predictor Factor for Common Carotid Arteries Intima Media Thickness in Patients with Clinically Inapparent Adrenal Adenomas. International Journal of Endocrinology, 2015, 2015, 1-7.	1.5	7
71	Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 485-487.	1.2	7
72	Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma, Life, 2021, 11, 266.	2.4	6

#	Article	IF	CITATIONS
73	Is Follow-up of Adrenal Incidentalomas Always Mandatory?. Endocrinology and Metabolism, 2020, 35, 26.	3.0	6
74	Limited Role of Hair Cortisol and Cortisone Measurement for Detecting Cortisol Autonomy in Patients With Adrenal Incidentalomas. Frontiers in Endocrinology, 2022, 13, 833514.	3.5	6
75	Adrenal pseudocyst mimiking cancer: A case report. Journal of Endocrinological Investigation, 2007, 30, 256-258.	3.3	5
76	May an Altered Hypothalamo–Pituitary–Adrenal Axis Contribute to Cortical Bone Damage in Primary Hyperparathyroidism?. Calcified Tissue International, 2009, 84, 425-429.	3.1	5
77	Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment. Endocrine, 2014, 45, 122-127.	2.3	5
78	Comparison of Reverse Triage with National Early Warning Score, Sequential Organ Failure Assessment and Charlson Comorbidity Index to classify medical inpatients of an Italian II level hospital according to their resource's need. Internal and Emergency Medicine, 2019, 14, 1073-1082.	2.0	5
79	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers, 2021, 13, 5831.	3.7	5
80	Desmopressin Test in Mild Cushing Syndrome. Archives of Internal Medicine, 2003, 163, 850.	3.8	3
81	Determination of salivary cortisol to assess time-related changes of the adrenal response to stress in critically ill patients. European Journal of Internal Medicine, 2019, 68, 66-70.	2.2	3
82	Inpatient disposition in overcrowded hospitals: is it safe and effective to use reverse triage and readmission screening tools for appropriate discharge? An observational prospective study of an Italian II level hospital. International Journal of Clinical Practice, 2019, 73, e13281.	1.7	3
83	Reversibility of Acute Adrenal Insufficiency After Hip Replacement: A Case Series. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 1669-1672.	1.2	3
84	Novel mutation of PPOX gene in a patient with abdominal pain and syndrome of inappropriate antidiuresis. Endocrine, 2018, 61, 403-406.	2.3	2
85	Acute Primary Adrenal Insufficiency after Hip Replacement in a Patient with Acute Intermittent Porphyria. Case Reports in Endocrinology, 2018, 2018, 1-4.	0.4	2
86	Multiple rebound-associated vertebral fractures after denosumab discontinuation: is prompt antiresorptive therapy always recommended, even when the risk of fracture seems low? A case report. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, .	1.2	2
87	May an adrenal incidentaloma change its nature?. Journal of Endocrinological Investigation, 2020, 43, 1301-1307.	3.3	1
88	Rapporto tra acromegalia e neoplasia: fantasia o realtÃ?. L Endocrinologo, 2007, 8, 37-53.	0.0	0
89	MIDNIGHT SALIVARY CORTISOL FOR DIAGNOSIS OF SUBCLINICAL CUSHING'S SYNDROME IN PATIENTS WITH CLINICALLY INAPPARENT ADRENOCORTICAL ADENOMA. European Journal of Internal Medicine, 2008, 19, S44.	2.2	0

90 Adrenal Incidentalomas. , 2018, , 303-307.

#	Article	IF	CITATIONS
91	Adrenal Hyperplasia as Possible Predictor of Mortality in Patients Admitted for Suspected SARS-Cov-2 Infection: A Prospective Study. Journal of the Endocrine Society, 2021, 5, A76-A76.	0.2	0
92	SAT-365 Prevalence and Clinical Features of Adrenal Incidentalomas: A Prospective Study in an Unselected Population. Journal of the Endocrine Society, 2019, 3, .	0.2	0
93	OR25-05 Increased Overall Mortality and Cardiovascular Morbidity in Patients with Adrenal Incidentalomas and Autonomous Cortisol Secretion: Results of the ENS@T NAPACA-Outcome Study. Journal of the Endocrine Society, 2020, 4, .	0.2	0